Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

The specific B-cell depleting anti-CD20 monoclonal antibody rituximab (RTX) is effective in terms of the treatment of various immune-mediated glomerulopathies. The administration of RTX has been shown to be reliable and highly effective particularly in patients with ANCA-associated vasculitis, which...

Full description

Bibliographic Details
Main Authors: Jan Miroslav Hartinger, Vojtech Kratky, Zdenka Hruskova, Ondrej Slanar, Vladimir Tesar
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
ANCA-associated vasculitis
membranous nephropathy
lupus nephritis
minimal change disease
ocrelizumab
vedolizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1024068/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1024068/full

Similar Items